Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 7, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

IgM multiple myeloma: pathologic evaluation of a rare entity.

Rebecca L King1, Matthew T Howard, Janice M Hodnefield

  • 1Dept of Pathology and Laboratory Medicine, The Children's Hospital of Philadelphia, 34th and Civic Center Blvd, Philadelphia, PA 19104;

American Journal of Clinical Pathology
|September 19, 2013
PubMed
Summary

Immunoglobulin M-producing multiple myeloma (IgM MM) often shows B-cell markers, distinguishing it from other myeloma types. Aberrant cyclin D1 expression or t(11;14) helps differentiate IgM MM from lymphoplasmacytic lymphoma (LPL).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Utility of MEF2B immunohistochemistry in distinguishing follicular lymphoma and marginal zone lymphoma in diagnostically challenging cases.

Journal of hematopathology·2026
Same author

Absent Cyclin D1 Expression in Myeloid Sarcomas Distinguishes From Malignant Histiocytic Neoplasms: When Morphologic Ambiguity is Deceptive.

The American journal of surgical pathology·2026
Same author

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Mayo Clinic Systematic Management and Risk-Adapted Therapy for Lymphoid Malignancies (lySMART) Consensus Guidelines 2026.

Mayo Clinic proceedings·2026
Same author

Genetic risk and immune dysregulation of classic Hodgkin lymphoma transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma: a multicentric study.

medRxiv : the preprint server for health sciences·2026
Same author

Next-generation sequencing for lymphoid neoplasms: Real-world utility from a clinical assay.

Human pathology·2026
Same author

Anatomical Localization-Based Analysis of Relapsed Secondary Central Nervous System Aggressive B-Cell Lymphoma (R-SCNSL).

Hematological oncology·2026

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • Multiple myeloma (MM) is a plasma cell malignancy.
  • Immunoglobulin M-producing multiple myeloma (IgM MM) presents unique diagnostic challenges.
  • Distinguishing IgM MM from lymphoplasmacytic lymphoma (LPL) is crucial for accurate diagnosis and treatment.

Purpose of the Study:

  • To characterize the pathological features of immunoglobulin M-producing multiple myeloma (IgM MM).
  • To identify key markers that differentiate IgM MM from other plasma cell neoplasms and lymphomas.
  • To clarify the diagnostic overlap between IgM MM and lymphoplasmacytic lymphoma (LPL).

Main Methods:

  • Review of clinicopathologic data for 15 cases of IgM MM.
  • Immunohistochemistry performed on bone marrow specimens.
Keywords:
Cyclin D1IgM multiple myelomaImmunophenotypeLymphoplasmacytic lymphomaPathology

More Related Videos

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

Related Experiment Videos

Last Updated: May 7, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

  • Analysis of B-cell and plasma cell markers, including CD19, CD20, CD45, CD5, CD117, and cyclin D1 expression.
  • Assessment for t(11;14) translocation.

    • Main Results:

    • 40% of IgM MM cases exhibited lymphoplasmacytoid cytology.
    • 80% of cases expressed B-cell markers (CD19, CD20, CD45).
    • Cyclin D1 expression and t(11;14) were common (73%), absent in LPL.
    • No cases expressed CD5 or had a CD5-positive B-cell population.

    Conclusions:

    • IgM MM frequently expresses B-cell-associated antigens, leading to diagnostic overlap with LPL.
    • Aberrant cyclin D1 expression or t(11;14) are key distinguishing features of IgM MM from LPL.
    • Evaluation for these abnormalities is recommended for IgM-associated lymphoplasmacytoid disorders.